Metvix

Methyl Aminolevulinate, the active ingredient in Metvix, is a photosensitizer (prodrug) presented as a cream for topical use. It is indicated for the treatment of actinic keratosis, a precancerous skin condition commonly occurring in sun‑exposed areas of adult patients. It is formulated for application on localized lesions and is activated by red light illumination in a clinical setting.

GNH USA supplies Metvix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Metvix is a topical photosensitizer used in the management of actinic keratosis, a precancerous skin disorder.

Actinic keratosis: reduces dysplastic lesions and helps prevent progression to squamous cell carcinoma.

Metvix may cause local skin reactions and, rarely, systemic adverse events.

Common Side Effects: - Erythema or redness at the application site - Edema or swelling of the treated area - Pain, burning or stinging sensation during or after illumination - Crusting, scabbing or mild ulceration - Itching or mild dermatitis

Serious or Rare Side Effects: - Severe allergic reaction or anaphylaxis - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Deep ulceration or secondary infection requiring medical intervention

Before using Metvix, consider the following safety measures.

Patient selection: use only in adults with a confirmed diagnosis of actinic keratosis. Sun exposure: avoid direct sunlight on treated skin for at least 48 hours after illumination. Concurrent photosensitizers: discontinue systemic photosensitizing drugs such as tetracyclines. Medical history: assess for photosensitivity disorders or severe skin conditions. Application site: ensure the skin is clean, dry and free of other topical agents before applying the cream. Store at room temperature: keep in the original container, protect from light and moisture.

Metvix can interact with other medications that affect photosensitivity or wound healing.

Major Interactions (Avoid): - Systemic photosensitizing agents (e.g., tetracyclines, sulfonamides): may increase phototoxic risk. - Topical retinoids applied concurrently: may enhance skin irritation. - Chemotherapy agents that cause photosensitivity: avoid simultaneous use.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for increased bleeding if ulceration occurs. - Immunosuppressants: may affect healing of treated lesions. - Other dermatologic lasers or light therapies: schedule with an adequate interval to prevent overlapping tissue damage.